Therapeutic Asset Ratings

13,157 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Cancer	Eli Lilly and Company	P2	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Hematopoietic And Lymphoid Cell Neoplasm	Masonic Cancer Center, University of Minnesota	P2	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Lymphoproliferative Syndrome	Emory University	P2	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Myelodysplastic/Myeloproliferative Neoplasm	Prelude Therapeutics	P2	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Prolymphocytic Leukemia	Acerta Pharma BV	P2	B (63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Disease Related To Solid Organ Transplantation	Jennifer Amengual	P2	B (63)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Ovarian Carcinoma	National Cancer Institute (NCI)	P2	B (63)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Plasma Cell Myeloma	Sanofi	P2	B (63)
INDOMETACINUM Prostate Cancer	Zhejiang University	P2	B (63)
Infliximab Colitis	Therakos LLC	P2	B (63)
Ipilimumab Rectal Cancer	Odense University Hospital	P2	B (63)
Ipilimumab Neuroblastoma	Children's National Research Institute	P2	B (63)
Ipilimumab Head And Neck Squamous Cell Carcinoma	Neonc Technologies, Inc.	P2	B (63)
Irinotecan Melanoma	Pfizer	P2	B (63)
Irinotecan Osteosarcoma	Milton S. Hershey Medical Center	P2	B (63)
LENALIDOMIDE Post-Transplant Lymphoproliferative Disease	Northwestern University	P2	B (63)
LENVATINIB Metastatic Melanoma	Yale University	P2	B (63)
LENVATINIB Head And Neck Squamous Cell Carcinoma	Salubris Biotherapeutics Inc	P2	B (63)
Mechlorethamine Mycosis Fungoides	Soligenix	P2	B (63)
MELPHALAN Acute Leukemia	Center for International Blood and Marrow Transplant Research	P2	B (63)
MELPHALAN Bone Marrow Failure Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (63)
MELPHALAN Chediak-Higashi Syndrome	Washington University School of Medicine	P2	B (63)
MELPHALAN Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (63)
MELPHALAN Myeloid Leukemia	Dana-Farber Cancer Institute	P2	B (63)
MELPHALAN Plasma Cell Leukemia	National Cancer Institute (NCI)	P2	B (63)

Showing 1001 to 1025 of 13,157 assets

PreviousPage 41 of 527Next